{
    "clinical_study": {
        "@rank": "124471", 
        "acronym": "RDNP-2012-02", 
        "arm_group": [
            {
                "arm_group_label": "Usual care", 
                "arm_group_type": "No Intervention", 
                "description": "participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets"
            }, 
            {
                "arm_group_label": "Renal Denervation Group", 
                "arm_group_type": "Experimental", 
                "description": "participants randomised to undergo the renal denervation procedure"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study investigating the safety and usefulness of the Renal Denervation Procedure\n      in reducing high blood pressure in people whose blood pressure is not adequatley controlled\n      despite already being treated with 2 blood pressure lowering drugs. This study is designed\n      to compare the effects renal denervation to a usual care group."
        }, 
        "brief_title": "Renal Denervation for Uncontrolled Hypertension", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "detailed_description": {
            "textblock": "This is a phase 4 randomised control trial of renal denervation for the treatment of\n      uncontrolled hypertension.\n\n      Previous studies have shown that the renal denervation procedure is safe and effective in\n      reducing blood pressure.\n\n      A total of 100 participants with uncontrolled blood pressure, treated with two blood\n      pressure lowering medications will be recruited into the study. Patients will be assigned to\n      one of two groups. Participants in Group 1 will be assigned to undergo the renal denervation\n      procedure. Participants in group 2 will undergo usual care, receiving additional\n      antihypertensive medication in an attempt to reach blood pressure targets.\n\n      The duration of this study is 36 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  BP \u2265140/90mmHg (or \u2265130/80mmHg for patients with diabetes)\n\n          -  concurrent treatment with 2 anti-hypertensive drugs\n\n        Exclusion Criteria:\n\n          -  renal artery anatomy ineligible for treatment\n\n          -  eGFR <15mL/min/1.73m2 (using MDRD calculation)\n\n          -  individual has had myocardial infarction, unstable angina or cerebrovascular accident\n             within 6 months of screening visit\n\n          -  female participants of child bearing potential must have negative pregnancy test\n             prior to treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02016573", 
            "org_study_id": "070/12", 
            "secondary_id": "1034397"
        }, 
        "intervention": {
            "arm_group_label": "Renal Denervation Group", 
            "description": "Renal Denervation Catheter", 
            "intervention_name": "Renal Denervation", 
            "intervention_type": "Device", 
            "other_name": "Symplicity Renal Denervation Catheter"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "renal denervation", 
            "blood pressure", 
            "cardiovascular risk", 
            "target organ damage", 
            "sympathetic activity"
        ], 
        "lastchanged_date": "December 16, 2013", 
        "location": {
            "contact": {
                "email": "markus.schlaich@bakeridi.edu.au", 
                "last_name": "Markus P Schlaich, MD", 
                "phone": "+61 3 8532 1502"
            }, 
            "facility": {
                "address": {
                    "city": "Melbourne", 
                    "country": "Australia", 
                    "state": "Victoria", 
                    "zip": "3004"
                }, 
                "name": "Alfred & Baker Medical Unit"
            }, 
            "investigator": {
                "last_name": "Markus P Schlaich, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "2", 
        "official_title": "Renal Denervation for Uncontrolled Hypertension", 
        "overall_contact": {
            "email": "markus.schlaich@bakeridi.edu.au", 
            "last_name": "Markus P Schlaich, MD", 
            "phone": "+61 3 8352 1502"
        }, 
        "overall_contact_backup": {
            "email": "petra.marusic@bakeridi.edu.au", 
            "last_name": "Petra Marusic, B.App.Sci.", 
            "phone": "+61 3 8532 1734"
        }, 
        "overall_official": {
            "affiliation": "Baker IDI Heart & Diabetes Institute", 
            "last_name": "Markus P Schlaich, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "percentage of patients who achieve BP target at 6 months post intervention", 
            "measure": "blood pressure control", 
            "safety_issue": "No", 
            "time_frame": "6 months post procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02016573"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "number of drugs required to reach target blood pressure", 
                "measure": "number of drugs required to reach target blood pressure", 
                "safety_issue": "No", 
                "time_frame": "baseline to 6 months"
            }, 
            {
                "description": "time to achieve blood pressure target", 
                "measure": "time to achieve blood pressure target", 
                "safety_issue": "No", 
                "time_frame": "baseline to 6 months"
            }, 
            {
                "description": "changes in muscle sympathetic nerve activity (MSNA), renal and whole body NE spillover", 
                "measure": "change in sympathetic nerve activity", 
                "safety_issue": "No", 
                "time_frame": "baseline to 6 months"
            }, 
            {
                "description": "Change in left Ventricular mass index, ejection fraction, diastolic filling", 
                "measure": "Change in left ventricular structure and function", 
                "safety_issue": "No", 
                "time_frame": "baseline to 6 months"
            }, 
            {
                "description": "Change in Quality of life as assessed be relevant questionnaires", 
                "measure": "Change in Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "baseline to 6 months"
            }, 
            {
                "description": "Plasma Renin Activity, aldosterone levels, eGFR, UACR, inflammatory markers, 24 hour urinary creatinine clearance, sodium, fasting glucose, fasting insulin, C-peptide, HOMA index, Lipid profile", 
                "measure": "Change in Serum and Urine Biochemistry", 
                "safety_issue": "Yes", 
                "time_frame": "baseline to 6 months"
            }, 
            {
                "description": "Change in markers of arterial stiffness as assessed by AI and PWV", 
                "measure": "Change in markes of arterial stiffness", 
                "safety_issue": "No", 
                "time_frame": "baseline to 6 months"
            }
        ], 
        "source": "Baker IDI Heart and Diabetes Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Baker IDI Heart and Diabetes Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}